What's in Takara Bio Inc.'s pipeline?

Takara Bio Inc. has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Takara Bio Inc.'s portfolio?

Top competitors by shared drug class: Akeso, AstraZeneca, Bio-Thera Solutions, Federation Francophone de Cancerologie Digestive, Healthpoint.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/takara-bio-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Takara Bio Inc. — Portfolio Competitive Intelligence Brief

Takara Bio Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
TBI-1301	TBI-1301	phase 3	CD47 antibody	CD47	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Akeso · 1 shared drug class
AstraZeneca · 1 shared drug class
Bio-Thera Solutions · 1 shared drug class
Federation Francophone de Cancerologie Digestive · 1 shared drug class
Healthpoint · 1 shared drug class
Providence Health & Services · 1 shared drug class
Shanghai Henlius Biotech · 1 shared drug class
Shenzhen Hornetcorn Bio-technology Company, LTD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Takara Bio Inc.:

Cite this brief

Drug Landscape (2026). Takara Bio Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/takara-bio-inc. Accessed 2026-05-16.